Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in Axial Psoriatic Arthritis
NCT04062695Phase 2Unknown
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Aug 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tofacitinib oral solution in psoriatic arthritis (PsA) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Total Berlin MRI Score for Sacroiliac Joints and Spine at 12 weeks. Status: unknown.
02
Drugs
tofacitinib oral solution
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT04062695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04062695.